Logo image of VIVE

VIVEVE MEDICAL INC (VIVE) Stock Fundamental Analysis

NASDAQ:VIVE - US92852W5013 - Common Stock

0.2201 USD
-0.04 (-15.35%)
Last: 1/18/2023, 8:00:02 PM
0.2151 USD
0 (-2.27%)
After Hours: 1/18/2023, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, VIVE scores 2 out of 10 in our fundamental rating. VIVE was compared to 190 industry peers in the Health Care Equipment & Supplies industry. The financial health of VIVE is average, but there are quite some concerns on its profitability. VIVE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VIVE had negative earnings in the past year.
In the past year VIVE has reported a negative cash flow from operations.
VIVE Yearly Net Income VS EBIT VS OCF VS FCFVIVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

VIVE has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VIVE Yearly ROA, ROE, ROICVIVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 1K -1K 2K 3K 4K

1.3 Margins

VIVE has a worse Gross Margin (16.39%) than 78.34% of its industry peers.
In the last couple of years the Gross Margin of VIVE has declined.
The Profit Margin and Operating Margin are not available for VIVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37.5%
GM growth 5Y-22.91%
VIVE Yearly Profit, Operating, Gross MarginsVIVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -200 -400 -600 -800

More info and screens

4

2. Health

2.1 Basic Checks

VIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VIVE has been increased compared to 1 year ago.
Compared to 1 year ago, VIVE has an improved debt to assets ratio.
VIVE Yearly Shares OutstandingVIVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M
VIVE Yearly Total Debt VS Total AssetsVIVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -34.95, we must say that VIVE is in the distress zone and has some risk of bankruptcy.
VIVE's Altman-Z score of -34.95 is on the low side compared to the rest of the industry. VIVE is outperformed by 94.47% of its industry peers.
There is no outstanding debt for VIVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.95
ROIC/WACCN/A
WACC8.03%
VIVE Yearly LT Debt VS Equity VS FCFVIVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 0.89 indicates that VIVE may have some problems paying its short term obligations.
The Current ratio of VIVE (0.89) is worse than 94.47% of its industry peers.
VIVE has a Quick Ratio of 0.89. This is a bad value and indicates that VIVE is not financially healthy enough and could expect problems in meeting its short term obligations.
VIVE has a Quick ratio of 0.74. This is amonst the worse of the industry: VIVE underperforms 88.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.74
VIVE Yearly Current Assets VS Current LiabilitesVIVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.74% over the past year.
The Revenue has been growing slightly by 2.34% in the past year.
VIVE shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.09% yearly.
EPS 1Y (TTM)32.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.94%
Revenue 1Y (TTM)2.34%
Revenue growth 3Y-29.73%
Revenue growth 5Y-2.09%
Sales Q2Q%4.21%

3.2 Future

VIVE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.12% yearly.
The Revenue is expected to grow by 50.55% on average over the next years. This is a very strong growth
EPS Next Y7.44%
EPS Next 2Y19.13%
EPS Next 3Y18.12%
EPS Next 5YN/A
Revenue Next Year7.41%
Revenue Next 2Y31.78%
Revenue Next 3Y50.55%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VIVE Yearly Revenue VS EstimatesVIVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
VIVE Yearly EPS VS EstimatesVIVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VIVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIVE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIVE Price Earnings VS Forward Price EarningsVIVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIVE Per share dataVIVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

VIVE's earnings are expected to grow with 18.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.13%
EPS Next 3Y18.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VIVE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVEVE MEDICAL INC

NASDAQ:VIVE (1/18/2023, 8:00:02 PM)

After market: 0.2151 0 (-2.27%)

0.2201

-0.04 (-15.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10 2022-11-10/amc
Earnings (Next)03-15 2023-03-15
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners2.98%
Ins Owner Change0%
Market Cap2.36M
Analysts85
Price Target4.77 (2067.2%)
Short Float %0.03%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.16%
Min EPS beat(2)1.96%
Max EPS beat(2)12.36%
EPS beat(4)3
Avg EPS beat(4)-0.41%
Min EPS beat(4)-18.64%
Max EPS beat(4)12.36%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-3.16%
Max Revenue beat(2)0%
Revenue beat(4)0
Avg Revenue beat(4)-3.09%
Min Revenue beat(4)-7.29%
Max Revenue beat(4)0%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.34%
EPS NY rev (1m)0%
EPS NY rev (3m)3.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.35
P/FCF N/A
P/OCF N/A
P/B 1.99
P/tB 1.99
EV/EBITDA N/A
EPS(TTM)-2.65
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-1.57
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS0.64
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.39%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37.5%
GM growth 5Y-22.91%
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.74
Altman-Z -34.95
F-Score4
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)64.33%
Cap/Depr(5y)133.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.94%
EPS Next Y7.44%
EPS Next 2Y19.13%
EPS Next 3Y18.12%
EPS Next 5YN/A
Revenue 1Y (TTM)2.34%
Revenue growth 3Y-29.73%
Revenue growth 5Y-2.09%
Sales Q2Q%4.21%
Revenue Next Year7.41%
Revenue Next 2Y31.78%
Revenue Next 3Y50.55%
Revenue Next 5YN/A
EBIT growth 1Y-6.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.4%
OCF growth 3YN/A
OCF growth 5YN/A